Replimune Group, Inc. REPL

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now liveWOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination wi

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be availa

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company’s Chief Commercial Officer. The inducement awards consist of a non-qualified stock option to purchase 150,000 shares of the Company's common stock and restricted stock units representing 100,000 shares of the Company's co

TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fisca

Replimune Group (NasdaqGS:REPL) received FDA accelerated approval for TUDRIQEV (RP1) in combination with nivolumab to treat advanced cutaneous melanoma after anti PD 1 therapy. This marks the first FDA approval for Replimune and follows an advisory committee review and complex regulatory process. The decision allows near term commercialisation and puts fresh focus on ongoing confirmatory trials and related legal and regulatory matters. Readers looking for more ideas in adjacent areas of...

AbCellera, Replimune and Airbnb reached fresh highs as strong drug data, new funding and better-than-expected earnings boosted investor confidence.

The firm priced about 9.7 million shares at $12.06 each, in line with Friday’s closing price.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response letters and a 10-3 advisory committee vote in late July recommending the therapy.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

The rally showed that investors are paying more attention to fast-growing healthcare and digital media companies.

Replimune said the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV, previously known as RP1, in combination with nivolumab.